Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Leflunomide in Unresectable Pancreatic Cancer
NCT06454383Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Jun 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of leflunomide in pancreatic ductal adenocarcinoma (PDAC), sponsored by City of Hope. Primary endpoints: Dose Limiting Toxicities at 28 days and Incidence of Adverse Events at 30 days. Started Jun 2024; status: recruiting.
02
Drugs
leflunomide
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06454383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06454383.